InspireMD (NYSE:NSPR) Now Covered by Maxim Group

Maxim Group initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued on Monday. The brokerage set a “buy” rating and a $6.00 price target on the stock. Maxim Group’s price objective points to a potential upside of 279.75% from the company’s current price.

InspireMD Stock Down 2.5%

NSPR opened at $1.58 on Monday. The company has a market capitalization of $66.95 million, a PE ratio of -2.11 and a beta of 0.72. InspireMD has a 52 week low of $1.51 and a 52 week high of $3.80. The firm has a 50-day simple moving average of $1.84 and a two-hundred day simple moving average of $2.16.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NSPR. Aberdeen Group plc increased its position in shares of InspireMD by 27.9% in the 4th quarter. Aberdeen Group plc now owns 3,173,364 shares of the company’s stock valued at $5,649,000 after purchasing an additional 692,247 shares during the last quarter. Velan Capital Investment Management LP increased its holdings in InspireMD by 137.1% in the third quarter. Velan Capital Investment Management LP now owns 2,143,698 shares of the company’s stock valued at $5,166,000 after buying an additional 1,239,669 shares during the last quarter. Parkman Healthcare Partners LLC raised its stake in InspireMD by 97.6% in the third quarter. Parkman Healthcare Partners LLC now owns 2,440,633 shares of the company’s stock valued at $5,882,000 after buying an additional 1,205,328 shares in the last quarter. Nantahala Capital Management LLC lifted its holdings in InspireMD by 45.7% during the 3rd quarter. Nantahala Capital Management LLC now owns 3,376,484 shares of the company’s stock worth $8,137,000 after buying an additional 1,058,467 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of InspireMD by 766.3% during the 3rd quarter. Millennium Management LLC now owns 147,423 shares of the company’s stock worth $355,000 after acquiring an additional 130,405 shares in the last quarter. Hedge funds and other institutional investors own 44.78% of the company’s stock.

InspireMD Company Profile

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.